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Abstract
Evaluation of the molecular status of 1p and 19q is a major rel-
evant diagnostic, prognostic, and predictive tool for oligodendrog-
lial brain tumors. Fluorescence in situ hybridization (FISH) is the
most commonly used technique for determining 1p and 19q allelic
losses, but it lacks fully standardized criteria for analysis. This lack of
standardization has led to interinstitutional disagreement in the inter-
pretation of results, thereby contributing to a ‘‘gray prognostic zone’’
that includes codeleted patients with an unexpectedly unfavorable
outcome. To optimize the prognostic potential of 1p/19q status deter-
mination, we first compared the actual criteria used for FISH reading
(i.e. different ratio cutoff values and the percentage of neoplastic nu-
clei carrying this chromosomal deletion) in a retrospective series of
143 pure and mixed oligodendroglial tumors. We then created a
‘‘weighted’’ FISH reading based on the merged ratio and percentage
of neoplastic cells carrying the deletion that was further differentially
modulated for 1p and 19q, respectively. This weighted codeletion
setting significantly strengthened the favorable prognostic power of
1p/19q losses by reducing the number of poor outcomes from 42% to
12.5% for patients with codeleted tumors. Thus, by identifying as
codeleted only those cases with more than 50% of cells having a
combined loss of 1p (using 0.7 ratio cutoff) and 19q (using 0.8 ratio
cutoff) arms, we created a molecular report that bears higher clinical
impact and strengthens the prognostic potential of 1p/19q allelic loss.
KeyWords: 1p/19q status, Fluorescence in situ hybridization analysis,
Glioma, Oligodendroglial tumors, Prognostic factor.
INTRODUCTION
In recent years, progress in molecular analysis has con-
tributed to recognizing important genetic alterations in brain
tumorigenesis, some of which are related to patient prognosis
(1, 2). The observation of different clinical behavior in glio-
mas presenting with the same histology and tumor grade has
led to the need for a better molecular characterization of these
lesions that could identify new useful biomarkers for both tu-
mor classification and patient management (1, 2). Among the
molecular markers identified as helpful for neurologic and neu-
ropathologic assessments, 1p/19q status analysis is one of the
most important tools with diagnostic, prognostic, and predictive
value in oligodendroglial-derived brain tumors (3Y21). It is well
known that codeletion of chromosome arms 1p and 19q defines
a subset of patients with better prognosis most likely because
of a higher sensitivity to genotoxic stress (21). Because of the
strong association between 1p/19q allelic loss and favorable
patient outcome, 1p/19q status is routinely investigated in pure
and mixed oligodendroglial tumors.
Fluorescence in situ hybridization (FISH) is the most
widely used technique for investigating 1p/19q status because
it allows the assessment of 1p/19q allelic loss on paraffin-
embedded tissue samples, thereby permitting matching of cell
morphology and genetic alterations (15, 22). To date, the in-
terpretation of FISH results for defining 1p/19q status has
not been standardized, and laboratories arbitrarily choose their
criteria to interpret FISH data based on ratio evaluation (be-
tween 1p/1q and 19q/19p), calculation of the percentage of
neoplastic nuclei carrying deletion, or according to guidelines
defined by the International Society of Pediatric Oncology
(ESIOP Neuroblastoma Study Group) (8, 10Y12, 15, 19,
22Y29). Furthermore, few authors have attempted to integrate
the ratio and percentage of deleted nuclei to determine 1p/19q
status (25, 30). The lack of a standard procedure for the inter-
pretation of FISH data has led to interinstitutional disagree-
ment on how to characterize 1p/19q molecular status, thereby
creating some confusion among clinicians regarding the prog-
nostic and predictive value of codeletion. This confusion most
likely accounts for a ‘‘gray prognostic zone,’’ which includes
codeleted patients with an unexpected unfavorable outcome
that is probably based on false-positive FISH results.
To optimize the prognostic role of 1p/19p status in pure
and mixed oligodendroglial tumors, we have tried to establish
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and compare different criteria for interpreting FISH results to
reduce the impact of the gray zone. Specifically, in this ret-
rospective series of 161 oligodendroglial tumors, we assessed
1p/19q status using FISH according to the following param-
eters: 1) 2 different ratio values; 2) the percentage of neo-
plastic nuclei carrying chromosomal deletion; and 3) a novel
integrated evaluation based on the ratio corrected by the per-
centage of neoplastic cells carrying codeletion, weighted dif-
ferently for 1p or 19q. In addition, we evaluated the prognostic
impact of an imbalanced 1p/19q deletion, as is observed in the
polysomy condition.
MATERIALS AND METHODS
Patients and Follow-up Analysis
A series of 161 cases of brain tumors with an oligoden-
droglial component were tested for 1p/19q status by FISH
between January 2004 and March 2012 and were retrospec-
tively retrieved from the pathology files of our department.
Hematoxylin and eosinYstained slides were independently re-
viewed by 2 pathologists (Paola Cassoni and Rebecca Senetta)
who were blinded to the patient outcome. The histologic diag-
nosis was made solely on hematoxylin and eosinYstained slides
before determining the FISH status. The tumors were classi-
fied according to the World Health Organization Classification
of Brain Tumors (31). In biopsy specimens, the diagnosis of
high-grade gliomas was made when necrosis, microvascular
proliferations, and/or mitotic activity (more than 2 mitoses/
biopsy) were present. After revision, 18 (11.2%) of 161 cases
were excluded from the study because they were recurrences,
brain tumors without an undoubtedly oligodendroglial com-
ponent, or cases with diagnostic disagreement between the
2 observers. The histologic diagnoses of the 143 cases included
in the study were as follows: 89 (62.2%) of 143 pure oligo-
dendrogliomas (O), 48 of 89 grade II (OII), and 41 of 89 grade
III (OIII); 38 (26.6%) of 143 mixed oligoastrocytomas (OA),
18 of 38 OA grade II (OAII), and 20 of 38 grade III (OAIII);
and 16 (11.2%) of 143 glioblastomas with an oligodendrog-
lial component (Table 1).
None of the patients had been previously treated with
chemotherapy or radiotherapy. Follow-up data concerning
the overall survival (OS) were available for all 143 cases.
Overall survival was defined as months from the date of init-
ial surgery to the date of patient death or last follow-up. Data
on disease-free survival (DFS) were obtained in 87 (60.8%)
of 143 patients and was calculated from the date of initial
surgery to the date of tumor progression/recurrence (defined
radiologically or clinically) or last follow-up.
The study was performed according to the standards of
the Institutional Ethical Committee and the Helsinki Decla-
ration of 1975, as revised in 1983, and approved by the in-
stitutional review board of our institution. All tissue samples
were anonymized by staff members who were not involved
in the study according to published procedures (32).
Fluorescence In Situ Hybridization
The FISH test was performed using the LSI 1p36/19q13
Dual-Color Probe Sets (Vysis/Abbott, Molecular Europe,
Wiesbaden, Germany). The Dual-Color Probe Set consists
of 2 separate probe mixtures: 1 probe set contains the LSI 1p36
Spectrum Orange test probe and the LSI 1q25 Spectrum
Green control probe; the other probe set contains the LSI 19q13
SpectrumOrange test probe and the LSI 19p13 SpectrumGreen
control probe. The paraffin sections were deparaffinized, air-
dried, incubated in pretreatment solution at 98-C for 15 minutes
in Heat Pretreatment Solution (Invitrogen, Carlsbad, CA), and
subsequently immersed in purified water. The slides were then
treated with Enzyme Reagent (Invitrogen) in a humidified box
for 30 to 40 minutes at room temperature and washed in puri-
fied water. After air dehydration, 10 KL of probe mixture was
applied to each sample. The slides were then coverslipped and
sealed with rubber cement. Slides and probes were codenatured
at 74-C for 5 minutes and hybridized at 37-C for 16 hours in
the dark using the Vysis HYBrite Denaturation/Hibridization
Unit (Vysis). A posthybridization wash was performed in 2
SSCY0.3% NP-40 at 73-C for 3 minutes. Finally, the slides
were dehydrated and mounted in antifade with DAPI (4¶,6-
diamidino-2-phenylindole; Abbott Molecular) and stored in
the dark before signal evaluation. An automated scanning sta-
tion, MetaSystems (Carl Zeiss MetaSystems, Thornwood, NY),
equipped with an AxioImager-Z1 epifluorescence microscope,
was used to determine 1p/19q status. The first step was signal
acquisition over 7 to 10 areas that were selected for each slide
by a dedicated operator. To choose regions with the most
neoplastic cells, areas with a high signal quality and good nu-
clei preservation were assessed. These areas were automati-
cally scanned, and 13 different consecutive focal planes were
made for each FISH signal to form a single bidimensional
image. For traditional reading, the automatically acquired im-
ages were transferred to Isis software (Zeiss) and stored in
dedicated files. The evaluation of hybridization signals was
then performed in 200 or more nonoverlapping nuclei, and the
TABLE 1. Correlation Between Histologic Diagnosis and 1p/19q Status (Ratio Cutoff for 1p e 0.7 or 0.8 and Ratio Cutoff for 19q e 0.8)
in 143 Brain Tumors With an Oligodendroglial Component
OII
(n = 48)
OIII
(n = 41)
OAII
(n = 18)
OAIII
(n = 20)
GBMO
(n = 16)
1p e0.7 (%) 1p e0.8 (%) 1p e0.7 (%) 1p e0.8 (%) 1p e0.7 (%) 1p e0.8 (%) 1p e0.7 (%) 1p e0.8 (%) 1p e0.7 (%) 1p e0.8 (%)
1p/19q codeleted 25 (52.1) 31 (64.6) 17 (41.5) 22 (53.6) 5 (27.8) 6 (33.3) 2 (10) 3 (15) 3 (18.7) 6 (37.5)
1p deleted 1 (2.1) 4 (8.4) 4 (9.7) 6 (14.6) 2 (11.1) 2 (11.1) 3 (15) 6 (30) 0 (0) 3 (18.8)
19q deleted 13 (27.1) 7 (14.5) 8 (19.5) 3 (7.4) 5 (27.8) 4 (22.3) 4 (20) 3 (15) 4 (25) 1 (6.2)
1p/19 not deleted 9 (18.7) 6 (12.5) 12 (29.3) 10 (24.4) 6 (33.3) 6 (33.3) 11 (55) 8 (40) 9 (56.3) 6 (37.5)
GBMO, glioblastoma with an oligodendroglial component; OII, oligodendroglioma grade II; OIII, oligodendroglioma grade III; OAII, oligoastrocytoma grade II; OAIII,
oligoastrocytoma grade III.
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nuclei counted displayed at least 2 green signals. The ratio of
1p/1q and 19q/19p was calculated by dividing the number of
orange and green signals.
For each case, FISH data were analyzed using criteria
as follows: 1) a cutoff ratio of less than or equal to 0.8 was
used to define 1p and 19q allelic losses; in addition, for 1p
chromosomal arm, we applied a more stringent ratio cutoff
equivalent to less than or equal to 0.7, as previously reported
(13); and 2) percentage of neoplastic nuclei carrying 1p and
19q deletions using greater than or equal to 50% as the cutoff
to define 1p and 19q deletions, as previously reported (24); 3)
an integrated evaluation, merging points 1 and 2 with fur-
ther subcategories, as detailed below. Finally, we investigated
the role of codeletion in chromosomal imbalance conditions
(polysomy) to determine its possible prognostic value, which
is debated in the literature (28).
Establishment of Specific Codeletion Criteria
To identify the most prognostically reliable evaluation
of codeletion (intended as a favorable indicator), we set differ-
ent criteria. As a premise, we specified a different ratio cutoff
regarding 1p exclusively, whereas the 19q cutoff for deletion
remained unchanged at less than or equal to 0.8. The reason for
this choice was based on preliminary evidence that 1p is the
most relevant chromosome for favorable prognosis, whereas
the 19q deletion can bear unfavorable prognostic value (16, 33).
Therefore, we designated our cutoff criteria for code-
letion as follows: 1) codeletion determined as ratio value less
than or equal to 0.8 for both 1p and 19q; 2) codeletion deter-
mined as ratio value less than or equal to 0.7 for 1p and less
than 0.8 for 19q; 3) codeletion determined as more than 50%
of neoplastic cells carrying both 1p and 19q deletion irrespec-
tive of the ratio value; 4) codeletion determined as ratio value
less than or equal to 0.8 for both 1p and 19q þ more than
50% of cells carrying the 1p deletion (merging points 1 and 3);
and 5) codeletion determined as ratio value less than or equal
to 0.7 for 1p and 0.8 for 19q and more than 50% of cells car-
rying the 1p deletion (merging points 2 and 3).
Statistical Analysis
The data were analyzed with SPSS Version 19 (SPSS,
Inc., Chicago, IL). A statistically significant probability value
was defined as p G 0.05. Univariate survival analysis was per-
formed using the Mantel-Cox test (34) and depicted by the
Kaplan-Meier method (35). Multivariate survival analysis was
performed using the Cox model.
RESULTS
Clinical and Pathologic Prognostic Variables:
Age, Extent of Surgical Resection,
and Histologic Grade
The patients included 81 men and 62 women, aged 22
to 81 years (mean, 51.5 years); 60 (42%) of 143 patients were
younger than 50 years and 83 (58%) of 143 were older.
Thirty-six (60%) of 60 patients younger than 50 years and 30
(37.5%) of 80 patients older than 50 years had a low-grade
glioma. By univariate analysis, age significantly correlated
with OS (p G 0.0001), identifying a subgroup of younger pa-
tients with a more favorable outcome (Fig. 1A). No correla-
tion was found with DFS (p = 0.27) (Fig. 1B). In addition,
young age (G50 years) retained its favorable prognostic value
FIGURE 1. Kaplan-Meier analyses of estimated overall survival OS (A) and disease-free survival (DFS) (B) in relation to patient age in
143 oligodendroglial brain tumors.
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not only in the overall series but also within the distinct not-
deleted and codeleted subgroups (p G 0.0001 and p = 0.001,
respectively).
Data concerning the extent of surgical resection were
available in 99 (69.2%) of 143 cases. More precisely, 19
(19.2%) of 99 patients underwent a biopsy; 59 (59.6%) of
99, a partial resection; 14 (14.2%) of 99, a subtotal resection;
and 7 (7%) of 99, a radical resection. There was no significant
difference in OS and DFS between these groups (OS, p = 0.07).
As expected, a histologic low tumor grade was related to
better OS (p G 0.0001) (Fig. 2A). Regarding the DFS, there
was a significant difference in tumor recurrence and pro-
gression between grades II and IV only (p = 0.008) (Fig. 2B).
FISH Data Interpretation
Ratio Cutoff Setting 1p e 0.8/19q e 0.8
Versus 1p e 0.7/19q e 0.8
We determined 1p/19q status using 2 different ratio
cutoff values to validate whether a more severe (e0.7) dele-
tion criterion for 1p could reduce the gray zone of unfavor-
able outcome despite codeletion. According to the 1p e 0.8/
19q e 0.8 ratio, there were 68 (47.6%) of 143 cases that
had both 1p and 19q allelic losses, 21 (14.7%) of 143 and 18
(12.6%) of 143 cases had isolated loss of 1p or 19q, respec-
tively, and 36 (25.1%) of 143 cases did not have codeletions
or single deletions (Table 1).
Using the more stringent ratio cutoff (e0.7) to define 1p
allelic loss, 16 (23.5%) of 68 of the prior codeleted cases were
redistributed into different subgroups; thus, codeletion was ob-
served in 52 (36.3%) of 143 cases (Table 1). By univariate
analysis independent of the 1p ratio cutoff, the subgroup of
cases with 1p/19q codeletion showed longer OS and DFS (1p e
0.8/19q e 0.8, OS, p = 0.002 and DFS, p = 0.03; 1p e 0.7/19q e
0.8, OS, p = 0.002 and DFS, p = 0.005) (Fig. 3). For DFS, the
use of the 0.7 cutoff for the 1p deletion strengthened the favor-
able prognostic value of codeletion. However, despite the use
of a different cutoff ratio and patient redistribution, the percent-
ages of codeleted patients who died at the end of follow-up
(42%) were equivalent (29 of 68 and 22 of 52 patients in 0.8
and 0.7 cutoff, respectively) (Supplemental Digital Content 1,
http://links.lww.com/NEN/A447). These results indicate that
restricting the cutoff ratio for 1p is not helpful in reducing
the gray zone of codeleted patients with poor outcome. In
addition, using the 0.8 ratio cutoff, the 19q allelic loss alone
identified a subset of patients with the worst prognosis
(Fig. 3AYC). The presence of an isolated 19q loss was not
closely associated with any specific tumor histologic type.
Ratio and Tumor Histology/Grade
Subdividing all cases according to the histologic type,
1p/19q codeletion (independently of the ratio applied [0.7
or 0.8]) retained prognostic significance only in pure oligo-
dendroglial tumors, identifying oligodendrogliomas with pro-
longed overall and progression-free survival (1p e 0.8/19q e
0.8, OS, p = 0.005 and DFS, p G 0.0001; 1p e 0.7/19q e 0.8, OS,
p = 0.006 and DFS, p G 0.0001) (Table 1). No correlation was
found in mixed oligodendroglial tumors of any histologic grade.
Similarly, grouping all cases according to the histologic
grade, regardless of tumor histotype, 1p/19q codeletion (with
any ratio) identified a subset of patients with a better prognosis
within grade II tumors only (1p e 0.8/19q e 0.8, OS, p = 0.03;
1p e 0.7/19q e 0.8, OS, p = 0.01). In addition, we observed
FIGURE 2. Kaplan-Meier analyses of estimated overall survival (OS) (A) and disease-free survival (DFS) (B) in relation to histologic
tumor grade in 143 oligodendroglial brain tumors.
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a trend for correlation between codeletion and OS in grade
IV tumors only when applying the ratio cutoff 1p e 0.7/19q e
0.8 (OS, p = 0.05).
Merging the previously reported data, we analyzed the
prognostic impact of 1p/19q status in pure oligodendrogliomas
according to histologic grade (grade II vs grade III). Applying
the ratio cutoff 1p e 0.8/19q e 0.8, codeletion identified a sub-
set of lesions with better outcome in both OII and OIII (OS,
p = 0.04 and p = 0.05, respectively). Conversely, no corre-
lation was found using the more severe cutoff (OS, p = 0.1
and p = 0.2, respectively), although there was a detectable
trend toward significance. In terms of DFS, with both ratios,
FIGURE 3. Kaplan-Meier analyses of estimated OS (A, B) and DFS (C, D) in relation to 1p/19q status, as assessed by applying a
1p e 0.8/19q e 0.8 ratio cutoff (AYC) and 1p e 0.7/19q e 0.8 ratio cutoff (BYD).
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codeletion was found to be significant only in OII (1p e 0.8/
19q e 0.8 and 1p e 0.7/19q e 0.8, p G 0.0001).
Percentage of Neoplastic Nuclei Deletion
For the second setting, we defined the 1p/19q molec-
ular status according to the ‘‘rough’’ percentage of neoplastic
nuclei carrying the deletion, independent of the ratio (in 11 of
143 cases, the data concerning the percentage of deleted nu-
clei were not available). The cutoff for codeletion was greater
than or equal to 50% of nuclei carrying loss of chromosomal
material from both arms (24). Forty-two (31.8%) of 132 cases
showed combined 1p and 19q loss; 24 (18.18%) of 132 and 18
(13.6%) of 132 cases showed single 1p or 19q allelic loss, re-
spectively; and 48 (36.3%) of 132 cases displayed 1p/19q main-
tenance. The subgroup of codeleted lesions showed a better
prognosis both in terms of OS and DFS (OS, p = 0.01; DFS,
p = 0.02) (Fig. 4). The percentage of codeleted patients who
died at the end of follow-up was 31.1% (16 of 42 cases) (Sup-
plemental Digital Content 1, http://links.lww.com/NEN/A447).
‘‘Weighted’’ Ratio: Ratio + Q50% of Neoplastic
Nuclei Carrying 1p Deletion in Codeleted Tumors
As previously reported, there was a statistical correlation
between codeletion and better patient outcome established by
using both the ratio and the rough percentage as independent
criteria. Thus, we tried to combine them to optimize the prog-
nostic value of FISH. We identified a subgroup of codeleted
tumors according to both previously reported ratio cutoff
values and then considered only codeleted cases with greater
than or equal to 50% of cells carrying 1p loss. The presence
on 1p deletion in greater than or equal to 50% of neoplas-
tic nuclei in codeleted cases identified a subset of patients
with better outcome (1p e 0.8/19q e 0.8, OS, p = 0.03 and DFS,
p = 0.04; 1p e 0.7/19q e 0.8, OS, p = 0.001) (Fig. 5) (Supple-
mental Digital Content 1, http://links.lww.com/NEN/A447).
Specifically, in the 1p e 0.8/19q e 0.8 codeleted group (63
patients), 9 (56.2%) of 16 patients who had less than 50% of
1p deleted cells died (Fig. 6). Strikingly, in the 1p e 0.7/19q
e 0.8 codeleted group (47 patients), all patients (100%) with
less than 50% of 1p deleted nuclei died (Fig. 6). In addition,
among 8 (12.7%) of 63 and 7 (14.9%) of 47 codeleted patients
showing 1p greater than or equal to 50% and a concomitant
19q loss in less than 50% of neoplastic cells, 7 (87.5%, using
1p e 0.8) of 8 and 6 (85.7%, using 1p e 0.7) of 7 respectively,
were still living. These data highlight the favorable effect
of 1p deletion and the unfavorable effect that 19q loss can
have on patient prognosis.
Multivariate Analysis
By multivariate Cox regression analysis, among all the
clinical, histologic, and molecular variables considered, the age
at diagnosis, histologic tumor grade, and 1p/19q deletion status
assessed using any reported criteria were independent prognos-
tic factors (Table 2). The combined (weighted) criteria based on
ratio plus cell percentage significantly strengthened the favorable
prognostic value of FISH, as assessed by codeletion (Table 2).
Concurrent 1p/19q Loss and Polysomy: Evaluation
of Prognostic Significance
Among the codeleted cases that were identified according
to the ratio criteria, 5 lesions showed polysomy (Q30% of
FIGURE 4. Kaplan-Meier analyses of estimated OS (A) and DFS (B) in relation to 1p/19q molecular status, according to the
‘‘rough’’ percentage of neoplastic nuclei carrying the deletion.
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neoplastic nuclei carrying 3 or more green signals for both
arms) (28). We identified 5 (7.9%) of 63 and 5 (10.6%) of 47
cases using the ratio cutoff of 1p e 0.8/19q e 0.8 or 1p e 0.7/
19q e 0.8, respectively. Two (40%) of 5 were grade II and 3
(60%) of 5 were grade III tumors. We did not observe any
significant difference in terms of OS or DFS among the
subgroups with and without polysomy (OS, p = 0.9 and DFS,
p = 0.7 for both ratio values).
DISCUSSION
To date, the 1p/19q codeletion remains the major fa-
vorable prognostic/predictive indicator for oligodendroglial
FIGURE 5. Kaplan-Meier analyses of estimated OS (A, B) and DFS (C, D) in the subgroup of codeleted cases, according to both
ratio cutoff values (1p e 0.8, AYC; 1p e 0.7, BYD) in relation to the presence of greater than or equal to 50% of neoplastic nuclei
carrying a 1p loss.
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tumors (3, 4, 6, 9, 16, 19, 21), but its efficacy may be impaired
because of the heterogeneity of methods used for its deter-
mination and to the lack of uniform reading criteria within the
specific techniques. A good concordance between FISH and
polymerase chain reactionYbased loss of heterozygosity has
been previously reported, and a recent study highlighted that
modulation of FISH interpretation criteria and additional de-
termination of 10q status could increase its predictive reli-
ability (25). The need for standardized protocols for FISH is
indicated by the relevant percentage of poor outcomes of pa-
tients with codeleted tumors, suggesting that interpretation of
data could be optimized. To achieve a significant reduction
of this gray zone of unexpected unfavorable outcomes in code-
leted oligodendroglial tumors, we created a weighted/scored
FISH interpretation that proved helpful in increasing the prog-
nostic stratification and that is easy to use in the daily diagnostic
assessment of 1p/19q status.
Our search for a gold standard in FISH data analysis
was organized through consecutive steps within a series of
143 tumors with an oligodendroglial component, either pure
(grade II and III oligodendrogliomas) or mixed (grade II and
III oligoastrocytomas and glioblastomas with an oligoden-
droglial component). First, we compared 2 ratio cutoff values
for 1p (0.8 and 0.7, respectively) in the presence of a fixed
FIGURE 6. Stratification of follow-up according to ratio cutoff values and percentage of neoplastic nuclei carrying a 1p loss.
TABLE 2. Multivariate Analysis of OS Based on Patient Age, Histologic Tumor Grade, and 1p/19q Codeletion Assessed Using Different
Criteria in 143 Brain Tumors With an Oligodendroglial Component
Variable
Ratio 1p e 0.8
19q e 0.8
Ratio 1p e 0.7
19q e 0.8
Q50% of
Neoplastic Cells
Carrying 1p and
19q Deletion
Ratio 1p e 0.8
19q e 0.8 +
Q50% of 1p
Deleted Nuclei
Ratio 1p e 0.7
19q e 0.8 +
Q50% of 1p
Deleted Nuclei
RR 95% CI p RR 95% CI p RR 95% CI p RR 95% CI p RR 95% CI p
Age G50 years 0.330 0.1Y0.5 G0.001 0.354 0.2Y0.6 G0.001 0.375 0.2Y0.6 G0.001 0.378 0.2Y0.6 0.001 0.390 0.2Y0.6 0.001
Histologic grade 0.512 0.3Y0.7 G0.001 0.501 0.3Y0.7 G0.001 0.462 0.3Y0.6 G0.001 0.488 0.3Y0.7 G0.001 0.486 0.3Y0.7 G0.001
1p/19q codeletion 0.468 0.2Y0.7 0.002 0.465 0.2Y0.7 0.003 0.440 0.2Y0.7 0.005 0.381 0.2Y0.6 0.001 0.325 0.1Y0.6 G0.001
95% CI, 95% confidence interval; RR, relative risk.
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0.8 cutoff for 19q and then weighted this analysis by setting
a further correction within the codeleted cases, linked to the
percentage of neoplastic cells carrying 1p deletion. Specifically,
we selected the 0.8 ratio cutoff as the most commonly used
and the 0.7 cutoff as the lowest reported in literature (10, 11, 13,
15, 30). This allowed us to identify and compare the varia-
tion of relative risk among different subclasses of codeleted
tumors. The 2 ratio cutoff values, as well as the cell percentage
‘‘restriction criteria,’’ have been applied within codeleted gli-
omas to tumors with 1p chromosome loss only because its
prognostic weight seems to be greater than 19q (33). Further-
more, there are conflicting results in the literature on the prog-
nostic value of solitary 19q loss: a negative prognostic role in
anaplastic gliomas identifying a subgroup of patients at worst
prognosis or a favorable role associated with long-term survival
in grade IV gliomas (16, 36Y38). In our series, 19q solitary de-
letion identified a subset of patients with a poorer DFS and OS
(only using the 0.8 cutoff ratio). Additional information on the
role of the 19q could come in the future from the comprehen-
sion of the effective clinical relevance of CIC mutations on the
retained 19q allele that were recently described to be linked to
IDH mutated oligodendogliomas (39).
Our first step was to compare the 0.8 1p/0.8 19q ratio
and the more stringent 0.7 1p/0.8 19q ratio. The percentage
of unfavorable outcomes within the 2 groups remained iden-
tical (42%), indicating that a more severe cutoff ratio was
useless for reducing the prognostic gray zone. As a second
step, we checked whether codeletion (defined as 950% of
cells carrying 1p and 19q deletions) was more effective than
ratio cutoff in identifying patients with better prognosis (18,
24, 29). The gray zone of unfavorable outcome was only
reduced from 42% to 38% of patients without significant
additional decrease of the relative risk. However, when we
merged the ratio and cell percentage criteria and restricted the
identification of codeleted patients to the cases with an ade-
quate ratio cutoff and more than 50% of cells carrying the 1 p
deletion, the favorable impact was increased and the relative
risk decreased from 0.468 to 0.325 (Table 2). The most fa-
vorable codeletion was defined as more that 50% of tumor
cells carrying the 1p deletion in a case showing a ratio cutoff of
0.7 for 1p and 0.8 for 19q; this setting regroups 69% of living
patients, irrespective of age, histotype, or tumor grade. Fur-
thermore, codeletion for ratio (according to 0.7 ratio cutoff)
combined with less than 50% cells with 1p loss seems to be
the most robust indicator of unfavorable prognosis, as 100% of
these patients in this series died (5 of 143) (Fig. 6).
Interestingly, further restriction of codeleted patients,
including only tumors with a ratio cutoff of 0.8, with more than
50% cells carrying the 1p loss and less that 50% of cells
carrying the 19q loss, allowed the identification of 87.5%
(7 of 8 cases) (similarly, 85.7% [6 of 7 cases] using 0.7 ratio
cutoff ) of living patients. These results demonstrate the exis-
tence of a balance between the 1p and 19q deletions, where the
best prognostic situation is that of an excess of cells with the 1p
loss and a minority with the 19q loss, within a codeletion setting.
In conclusion, we suggest that the most prognostically
reliable FISH report in oligodendroglial tumors should define
as codeleted tumors those with a ratio cutoff less than or equal
to 0.7 and more than 50% of cells with the 1p loss, eventually
with further a restriction to cases in which a minority of cells
have the 19q deletion. A further validation in other dedicated
laboratories will help in testing this new weighted FISH reading
to assess the consequence of intercenter variability in data in-
terpretation and technical procedures.
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